KR20110004852A - 포사코나졸 및 ｈｐｍｃａｓ를 바람직하게 포함하는 고체 분산액 중의 경구 약제학적 조성물 - Google Patents

포사코나졸 및 ｈｐｍｃａｓ를 바람직하게 포함하는 고체 분산액 중의 경구 약제학적 조성물

Info

Publication number
KR20110004852A
KR20110004852A KR1020107023010A KR20107023010A KR20110004852A KR 20110004852 A KR20110004852 A KR 20110004852A KR 1020107023010 A KR1020107023010 A KR 1020107023010A KR 20107023010 A KR20107023010 A KR 20107023010A KR 20110004852 A KR20110004852 A KR 20110004852A
Authority
KR
South Korea
Prior art keywords
posaconazole
composition
hpmc
polymer
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107023010A
Other languages
English (en)
Korean (ko)
Inventor
래리 윤 팡
데이비드 해리스
고팔 크리쉬나
2세 알렌 이. 모톤
러셀 씨. 프레스티피노
마크 스테인맨
지안솅 완
헤티 앤 와스킨
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110004852(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20110004852A publication Critical patent/KR20110004852A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107023010A 2008-04-15 2009-04-15 포사코나졸 및 ｈｐｍｃａｓ를 바람직하게 포함하는 고체 분산액 중의 경구 약제학적 조성물 Ceased KR20110004852A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045,177 2008-04-15
US16648709P 2009-04-03 2009-04-03
US61/166,487 2009-04-03

Publications (1)

Publication Number Publication Date
KR20110004852A true KR20110004852A (ko) 2011-01-14

Family

ID=41199703

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107023010A Ceased KR20110004852A (ko) 2008-04-15 2009-04-15 포사코나졸 및 ｈｐｍｃａｓ를 바람직하게 포함하는 고체 분산액 중의 경구 약제학적 조성물

Country Status (19)

Country Link
US (2) US20110123627A1 (enExample)
EP (1) EP2285351A2 (enExample)
JP (3) JP2011516612A (enExample)
KR (1) KR20110004852A (enExample)
CN (2) CN104983701A (enExample)
AR (1) AR072858A1 (enExample)
AU (1) AU2009236289B2 (enExample)
BR (1) BRPI0910627A2 (enExample)
CA (1) CA2720849A1 (enExample)
CL (1) CL2009000902A1 (enExample)
CO (1) CO6311066A2 (enExample)
MX (1) MX2010011295A (enExample)
NZ (1) NZ588460A (enExample)
PE (1) PE20091778A1 (enExample)
PH (1) PH12015500492A1 (enExample)
SG (1) SG10201403986UA (enExample)
TW (1) TWI388324B (enExample)
WO (1) WO2009129300A2 (enExample)
ZA (1) ZA201007370B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160015234A (ko) * 2013-06-03 2016-02-12 신에쓰 가가꾸 고교 가부시끼가이샤 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
EP2837391B1 (en) * 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
CN104971045A (zh) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
WO2017025292A1 (en) 2015-08-08 2017-02-16 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP4424308A3 (en) 2016-02-26 2024-12-04 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
US10702520B1 (en) 2019-01-29 2020-07-07 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US20230149452A1 (en) * 2020-04-06 2023-05-18 Yogesh BENDALE Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof
US20240293399A1 (en) 2020-08-13 2024-09-05 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
WO2023012378A1 (en) 2021-11-25 2023-02-09 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20060062848A1 (en) * 2004-09-17 2006-03-23 Nektar Therapeutics Uk Limited Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160015234A (ko) * 2013-06-03 2016-02-12 신에쓰 가가꾸 고교 가부시끼가이샤 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법

Also Published As

Publication number Publication date
MX2010011295A (es) 2010-11-12
AU2009236289A1 (en) 2009-10-22
US20110123627A1 (en) 2011-05-26
PH12015500492A1 (en) 2017-04-10
EP2285351A2 (en) 2011-02-23
WO2009129300A3 (en) 2010-02-11
JP2016074698A (ja) 2016-05-12
PE20091778A1 (es) 2009-11-13
CN104983701A (zh) 2015-10-21
NZ588460A (en) 2012-07-27
AU2009236289B2 (en) 2014-08-21
CL2009000902A1 (es) 2010-07-23
TW200946121A (en) 2009-11-16
CN102065842A (zh) 2011-05-18
AR072858A1 (es) 2010-09-29
JP2014139230A (ja) 2014-07-31
TWI388324B (zh) 2013-03-11
JP2011516612A (ja) 2011-05-26
BRPI0910627A2 (pt) 2015-09-22
CA2720849A1 (en) 2009-10-22
ZA201007370B (en) 2011-06-29
SG10201403986UA (en) 2014-10-30
US20150150990A1 (en) 2015-06-04
WO2009129300A2 (en) 2009-10-22
CO6311066A2 (es) 2011-08-22

Similar Documents

Publication Publication Date Title
KR20110004852A (ko) 포사코나졸 및 ｈｐｍｃａｓ를 바람직하게 포함하는 고체 분산액 중의 경구 약제학적 조성물
US11925709B2 (en) Tablet formulation for CGRP active compounds
US8354122B2 (en) Solid dispersion preparation
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
EP2953615B1 (en) Solid dispersion comprising amorphous cilostazol
EP4346773B1 (en) A plurality of tasquinimod particles and use thereof
CN113081970A (zh) 一种环孢素固体分散体及其片剂制备方法
AU2014265059A1 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
US20250000839A1 (en) Pharmaceutical composition comprising enavogliflozin
TR2023008262A2 (tr) Fi̇lm kapli bri̇varasetam tabletleri̇
HK1218618B (en) Solid dispersion comprising amorphous cilostazol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140226

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150903

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150903

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I